MedTrace Logo

Dosing of Ketorolac in the Emergency Department

NCT03464461 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 289

Last updated 2024-11-05

Study results available
· View outcomes & findings →

Summary

The optimal dose of ketorolac in the Emergency Department setting is no clear. We will compare 3 doses to determine the optimal dose.

Conditions

  • Acute Pain

Interventions

DRUG

Ketorolac

IV drug

Sponsors & Collaborators

  • University of Missouri-Columbia

    lead OTHER

Principal Investigators

  • Matthew Robinson, MD · University of Missouri-Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2024-05-30
Completion
2024-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03464461 on ClinicalTrials.gov